BOULDER, Colo., July 27, 2015 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2015 and hold a conference call to discuss those results on Monday, August 3, 2015. Ron Squarer, Chief Executive Officer will lead the call.

http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO



    Date:                                    Monday, August 3, 2015

    Time:                                    9:00 a.m. Eastern Time

    Toll-Free:                               (844) 464-3927

    Toll:                                    (765) 507-2598

    Pass Code:                                                      68380312

    Webcast, including Replay and Conference Call Slides:

    http://edge.media-server.com/m/p/999aon7i/lan/en

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.



    CONTACT:                         Tricia Haugeto

                                     Array BioPharma Inc.

                                     (303) 386-1193

                                     thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2015-on-august-3-2015-300119132.html

SOURCE Array BioPharma Inc.